Sanofi (SNYNF) Work In Process (2015 - 2018)

Sanofi (SNYNF) posted Work In Process of $4.7 billion for Q4 2018, up 7.34% sequentially from $4.3 billion in Q4 2017, and up 7.34% YoY from $4.3 billion in Q4 2017.

Sanofi (SNYNF) Work In Process (2015 - 2018) Analysis & Trends

Sanofi (SNYNF) has 4 years of Work In Process data on file, last reported at $4.7 billion in Q4 2018.

  • Quarterly Work In Process rose 7.34% year-over-year to $4.7 billion in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $4.7 billion (up 7.34% YoY) and the FY2018 annual result came in at $4.7 billion, up 11.91% from the prior year.
  • Work In Process improved to $4.7 billion in Q4 2018 per SNYNF's latest filing, from $4.3 billion in the prior quarter.
  • The five-year high for Work In Process was $4.7 billion in Q4 2018, with the low at $3.8 billion in Q4 2015.
  • Average Work In Process over 4 years is $4.2 billion, with a median of $4.2 billion recorded in 2016.
  • Year-over-year, Work In Process increased 7.56% in 2016 and grew 5.89% in 2017.
  • Sanofi's Work In Process stood at $3.8 billion in 2015, then increased by 7.56% to $4.1 billion in 2016, then advanced by 5.89% to $4.3 billion in 2017, then advanced by 7.34% to $4.7 billion in 2018.
  • Business Quant data shows SNYNF's Work In Process at $4.7 billion in Q4 2018, $4.3 billion in Q4 2017, and $4.1 billion in Q4 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Sanofi - - 9.49 Bn

Historic Data

Download Data
DateValue
Dec 31, 2018 4.67 Bn
Dec 31, 2017 4.35 Bn
Dec 31, 2016 4.11 Bn
Dec 31, 2015 3.82 Bn